Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
1.344
-0.006 (-0.43%)
Mar 4, 2026, 10:30 AM EST - Market open
Cyclerion Therapeutics Employees
Cyclerion Therapeutics had 1 employees as of September 30, 2025. The number of employees did not change compared to the same quarter last year.
Employees
1
Change
n/a
Growth
n/a
Revenue / Employee
$2,855,000
Profits / Employee
-$2,199,000
Market Cap
5.12M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 1 | 0 | - |
| Jun 30, 2025 | 1 | 0 | - |
| Mar 31, 2025 | 1 | 0 | - |
| Dec 31, 2024 | 1 | 0 | - |
| Sep 30, 2024 | 1 | 0 | - |
| Jun 30, 2024 | 1 | - | - |
| Mar 31, 2024 | 1 | -15 | -93.75% |
| Dec 31, 2023 | 1 | -15 | -93.75% |
| Dec 31, 2022 | 16 | -16 | -50.00% |
| Dec 31, 2021 | 32 | -2 | -5.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 36 |
| Calidi Biotherapeutics | 28 |
| VivoSim Labs | 14 |
| Genprex | 13 |
| BioRestorative Therapies | 11 |
| Processa Pharmaceuticals | 10 |
| MetaVia | 9 |
| Indaptus Therapeutics | 7 |
CYCN News
- 15 days ago - Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board - GlobeNewsWire
- 2 months ago - Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript - Seeking Alpha
- 2 months ago - Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewsWire
- 5 months ago - Cyclerion Therapeutics, Inc. - Pre Recorded Special Call - Seeking Alpha
- 5 months ago - Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company - GlobeNewsWire
- 1 year ago - Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewsWire
- 1 year ago - Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewsWire
- 2 years ago - Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewsWire